| Name: | Acarbose EP Impurity F |
| Catalogue No. | VL5070007 |
| CAS No. | N/A |
| Molecular Formula | C31H53NO23 |
| Molecular Weight | 807.76 |
| Status | Under Development |
| IUPAC Name | 2-(((2R,3R,4R,5S,6R)-5-(((2R,3R,4R,5S,6R)-5-(((2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-(((1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl)amino)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
| Description | Acarbose EP Impurity F is an impurity formed during the industrial production of Acarbose, which is generated by certain strains of Actinoplanes utahensis, which is utilized in the treatment of type 2 diabetes mellitus that is a complicated progressive disorder observed for its morbidity and mortality. |
| References | Wang, Ya-Jun, et al. “Analysis and Determination of Anti-Diabetes Drug Acarbose and Its Structural Analogs.” Current Pharmaceutical Analysis, vol. 7, no. 1, Feb. 2011, pp. 12–20, https://doi.org/10.2174/157341211794708721. Azam Sadat Montazeri, et al. “Development and Validation of a Stability-Indicating HPLC Method for the Determination of Acarbose in Pharmaceutical Dosage Forms.” Journal of Analytical Chemistry, vol. 73, no. 9, Sept. 2018, pp. 910–16, https://doi.org/10.1134/s1061934818090071. |
